Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice

Abstract Background Recent advances in gene editing technology have opened up new avenues for in vivo gene therapy, which holds great promise as a potential treatment method for dilated cardiomyopathy (DCM). The CRISPR-Cas13 system has been shown to be an effective tool for knocking down RNA express...

Full description

Bibliographic Details
Published in:Cell & Bioscience
Main Authors: Jiacheng Li, He Xuan, Xin Kuang, Yahuan Li, Hong Lian, Nie Yu
Format: Article
Language:English
Published: BMC 2024-01-01
Subjects:
PspCas13b
Cardiac troponin T
Dilated cardimyopathy
Gene therapy
Online Access:https://doi.org/10.1186/s13578-023-01143-y

Internet

https://doi.org/10.1186/s13578-023-01143-y

Similar Items